Regeneron Pharmaceuticals Inc (REGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $789.03 (-0.05%), Market cap $66.02B, P/E ratio 15.38, 52-week low–high $483.07 ~ $812.27.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent inje
Financial statements, price targets, institutional (13F) holdings and related news for Regeneron Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Regeneron Pharmaceuticals Inc trades at $789.03 (-0.05%). Real-time quotes and charts are available on BlackAll Trade.
Regeneron Pharmaceuticals Inc has a market cap of about $66.02B. Its P/E ratio is 15.38.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, alle